Tanaka K, Inoue H, Miki H, Masuda E, Kitaichi M, Komaki K, Uyama T, Monden Y
The Second Department of Surgery, School of Medicine, The University of Tokushima, Japan.
Br J Cancer. 1997;76(5):594-9. doi: 10.1038/bjc.1997.431.
We have demonstrated the expression of thyrotropin receptor (TSH-R) in thyroid neoplasms (13 adenomas, 21 papillary carcinomas, two follicular carcinomas) and adjacent normal thyroid using the monoclonal antibody against human TSH-R and have also demonstrated a relationship between prognostic scores and the expression of TSH-R. Among the adenomas, eight showed an intensity similar to that of normal thyroid and five showed a higher intensity than normal. Two tumours exhibited heterogeneous distribution of TSH-R. Among the papillary carcinomas, seven showed similar intensity to normal tissue and four showed higher intensity and ten showed weaker intensity. Eight tumours showed heterogeneous distribution of the stain. Among the follicular carcinomas, one showed similar intensity to normal tissue and the other exhibited weaker intensity. Both cases showed homogeneous distribution of TSH-R. The adenomas never showed a weaker intensity than normal thyroid, but various intensities of TSH-R occurred in differentiated carcinomas. There was no significant relationship between the clinical data and the signal intensity in the adenomas. Among the papillary carcinomas, however, the group with weaker intensity had significantly poorer prognostic scores than the other two groups. Thus, we assume that low TSH-R may be expressed by the clinically high-risk group of patients with papillary thyroid carcinoma.
我们使用抗人促甲状腺激素受体（TSH-R）的单克隆抗体，证实了促甲状腺激素受体（TSH-R）在甲状腺肿瘤（13例腺瘤、21例乳头状癌、2例滤泡癌）及相邻正常甲状腺组织中的表达，并且还证实了预后评分与TSH-R表达之间的关系。在腺瘤中，8例的表达强度与正常甲状腺相似，5例的表达强度高于正常。2例肿瘤表现出TSH-R的异质性分布。在乳头状癌中，7例的表达强度与正常组织相似，4例的表达强度较高，10例的表达强度较弱。8例肿瘤表现出染色的异质性分布。在滤泡癌中，1例的表达强度与正常组织相似，另1例的表达强度较弱。2例均表现出TSH-R的均匀分布。腺瘤的表达强度从未低于正常甲状腺，但在分化型癌中出现了不同强度的TSH-R。腺瘤的临床数据与信号强度之间无显著关系。然而，在乳头状癌中，表达强度较弱的组的预后评分明显低于其他两组。因此，我们推测甲状腺乳头状癌临床高危患者组可能表达低水平的TSH-R。
